{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T06:27:01Z","timestamp":1794724021931,"version":"4.9.1"},"reference-count":141,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.eururo.2024.03.027","type":"journal-article","created":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T03:41:17Z","timestamp":1712979677000},"page":"148-163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1419,"title":["EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer\u20142024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent"],"prefix":"10.1016","volume":"86","author":[{"given":"Philip","family":"Cornford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick C.N.","family":"van den Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Briers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Van den Broeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Brunckhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Darraugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Eberli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"De Meerleer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Farolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Gandaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann M.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lardas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert J.L.H.","family":"van Leenders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Liew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefania","family":"Linares Espinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Oldenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M.","family":"van Oort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela E.","family":"Oprea-Lager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Ploussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rouvi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo G.","family":"Schoots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1918-2073","authenticated-orcid":false,"given":"Natasha","family":"Schouten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Stranne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter-Paul M.","family":"Willemse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Tilki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2024.03.027_b0005","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer\u20142020 update. Part 1: screening, diagnosis and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0010","series-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer","author":"Cornford","year":"2024"},{"key":"10.1016\/j.eururo.2024.03.027_b0015","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/bmj.39493.646875.AE","article-title":"Going from evidence to recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2024.03.027_b0020","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","article-title":"Recent global patterns in prostate cancer incidence and mortality rates","volume":"77","author":"Culp","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0025","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/pros.22925","article-title":"Prostate cancer risk prediction based on complete prostate cancer family history","volume":"75","author":"Albright","year":"2015","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2024.03.027_b0030","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00345-011-0801-1","article-title":"Familial risk and familial survival in prostate cancer","volume":"30","author":"Hemminki","year":"2012","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0035","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41391-021-00341-4","article-title":"Common genetic and clinical risk factors: association with fatal prostate cancer in the cohort of Swedish men","volume":"24","author":"Huynh-Le","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2024.03.027_b0040","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.eururo.2019.08.019","article-title":"Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRAC2 mutation carriers","volume":"76","author":"Page","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0045","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/S1470-2045(21)00522-2","article-title":"A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study","volume":"22","author":"Bancroft","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.03.027_b0050","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/s41416-021-01675-5","article-title":"BRAC1 and BRAC2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis","volume":"126","author":"Nyberg","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2024.03.027_b0055","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.juro.2014.06.071","article-title":"Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from 5-year median follow-up of 3 registries","volume":"193","author":"Haider","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0060","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11934-017-0695-6","article-title":"Testosterone therapy on active surveillance and following definitive treatment for prostate cancer","volume":"18","author":"Golla","year":"2017","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.eururo.2024.03.027_b0065","series-title":"TNM classification of malignant tumors","author":"Brierley","year":"2017"},{"key":"10.1016\/j.eururo.2024.03.027_b0070","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","article-title":"E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET","volume":"48","author":"Ceci","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2024.03.027_b0075","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/01.pas.0000173646.99337.b1","article-title":"The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma","volume":"29","author":"Epstein","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.eururo.2024.03.027_b0080","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/PAS.0000000000001497","article-title":"The 2019 International Society of Urological Pathology (ISUP) consensus conference on grading of prostatic carcinoma","volume":"44","author":"van Leenders","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.eururo.2024.03.027_b0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002063","article-title":"Improving clinical risk stratification at diagnosis in primary prostate cancer: a prognostic modelling study","volume":"13","author":"Gnanapragasam","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.eururo.2024.03.027_b0090","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12916-018-1019-5","article-title":"The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study","volume":"16","author":"Gnanapragasam","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.eururo.2024.03.027_b0095","article-title":"Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis","volume":"362","author":"Ilic","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2024.03.027_b0100","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","article-title":"A 16-yr follow-up of the European Randomized Study of Screening for Prostate Cancer","volume":"76","author":"Hugosson","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/21681805.2017.1411392","article-title":"Eighteen-year follow-up of the Goteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality","volume":"52","author":"Hugosson","year":"2018","journal-title":"Scand J Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0110","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.eururo.2023.03.016","article-title":"A detailed evaluation of the effect of prostate-specific antigen-based screening on morbidity and mortality of prostate cancer: 21-year follow-up results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer","volume":"84","author":"de Vos","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0115","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejca.2019.04.031","article-title":"Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients","volume":"116","author":"Boyle","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2024.03.027_b0120","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw165","article-title":"Repeat prostate-specific antigen tests before prostate biopsy decisions","volume":"108","author":"Nordstrom","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2024.03.027_b0125","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S1470-2045(22)00016-X","article-title":"Multiparametric ultrasound versus multiparametric MRI to diagnose prostate cancer (CADMUS): a prospective, multicentre, paired-cohort, confirmatory study","volume":"23","author":"Grey","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.03.027_b0130","article-title":"Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer","volume":"4","author":"Drost","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2024.03.027_b0135","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","article-title":"MRI-targeted or standard biopsy for prostate-cancer diagnosis","volume":"378","author":"Kasivisvanathan","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.03.027_b0140","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(18)30569-2","article-title":"Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study","volume":"20","author":"Rouviere","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.03.027_b0145","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.euo.2019.06.005","article-title":"Is there still a need for repeated systematic biopsies in patients with previous negative biopsies in the era of magnetic resonance imaging-targeted biopsies of the prostate?","volume":"3","author":"Exterkate","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.03.027_b0150","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/bju.15277","article-title":"Risk-adapted biopsy decision based on prostate magnetic resonance imaging and prostate-specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation","volume":"127","author":"Schoots","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.03.027_b0155","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.eururo.2018.06.022","article-title":"Prostate cancer diagnostics using a combination of the Stockholm3 blood test and multiparametric magnetic resonance imaging","volume":"74","author":"Gronberg","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0160","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S1470-2045(21)00348-X","article-title":"Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial","volume":"22","author":"Nordstrom","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.03.027_b0165","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.euo.2022.04.006","article-title":"Diagnostic performance of prostate-specific membrane antigen positron emission tomography-targeted biopsy for detection of clinically significant prostate cancer: a systematic review and meta-analysis","volume":"5","author":"Kawada","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.03.027_b0170","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","article-title":"The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study","volume":"80","author":"Emmett","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0175","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/bju.15906","article-title":"A systematic review on the outcomes of local anaesthetic transperineal prostate biopsy","volume":"131","author":"Kanagarajah","year":"2023","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.03.027_b0180","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S0022-5347(05)00957-2","article-title":"Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review","volume":"175","author":"Eichler","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0185","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.eururo.2018.11.023","volume":"75","author":"van der Leest","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0190","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.eururo.2018.11.040","article-title":"The FUTURE trial: a multicenter randomised controlled trial on target biopsy techniques based on magnetic resonance imaging in the diagnosis of prostate cancer in patients with prior negative biopsies","volume":"75","author":"Wegelin","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0195","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.euros.2022.04.001","article-title":"Diagnostic performance of a magnetic resonance imaging-directed targeted plus regional biopsy approach in prostate cancer diagnosis: a systematic review and meta-analysis","volume":"40","author":"Hagens","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.eururo.2024.03.027_b0200","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.eururo.2022.01.008","article-title":"Targeted prostate biopsy: umbra, penumbra, and value of perilesional sampling","volume":"82","author":"Brisbane","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0205","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41391-022-00620-8","article-title":"Optimizing multiparametric magnetic resonance imaging-targeted biopsy and detection of clinically significant prostate cancer: the role of perilesional sampling","volume":"26","author":"Noujeim","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2024.03.027_b0210","doi-asserted-by":"crossref","first-page":"e860","DOI":"10.1016\/j.clgc.2019.05.006","article-title":"Transperineal magnetic resonance imaging-targeted biopsy may perform better than transrectal route in the detection of clinically significant prostate cancer: systematic review and meta-analysis","volume":"17","author":"Tu","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2024.03.027_b0215","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/pcan.2017.13","article-title":"Magnetic resonance imaging targeted transperineal prostate biopsy: a local anaesthetic approach","volume":"20","author":"Bass","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2024.03.027_b0220","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.urology.2016.12.011","article-title":"Prostate biopsy-related infection: a systematic review of risk factors, prevention strategies, and management approaches","volume":"104","author":"Roberts","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2024.03.027_b0225","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.euf.2018.11.009","article-title":"Update on strategies to reduce infectious complications after prostate biopsy","volume":"5","author":"Pilatz","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2024.03.027_b0230","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/modpathol.2016.49","article-title":"Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy","volume":"29","author":"Kweldam","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.eururo.2024.03.027_b0235","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/pros.23326","article-title":"Intraductal carcinoma of the prostate on diagnostic needle biopsy predicts prostate cancer mortality: a population-based study","volume":"77","author":"Saeter","year":"2017","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2024.03.027_b0240","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1007\/s00345-019-03053-6","article-title":"Decreased accuracy of the prostate cancer EAU risk group classification in the era of imaging-guided diagnostic pathway: proposal for a new classification based on MRI-targeted biopsies and early oncologic outcomes after surgery","volume":"38","author":"Ploussard","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0245","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.urology.2020.08.089","article-title":"Multiparametric magnetic resonance imaging should be preferred over digital rectal examination for prostate cancer local staging and disease risk classification","volume":"147","author":"Soeterik","year":"2021","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2024.03.027_b0250","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.crad.2007.05.022","article-title":"The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis","volume":"63","author":"Hovels","year":"2008","journal-title":"Clin Radiol"},{"key":"10.1016\/j.eururo.2024.03.027_b0255","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.3390\/cancers15061683","volume":"15","author":"Di Pierro","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.eururo.2024.03.027_b0260","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"Perera","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0265","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s00256-014-1903-9","article-title":"Comparison of choline-PET\/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis","volume":"43","author":"Shen","year":"2014","journal-title":"Skelet Radiol"},{"key":"10.1016\/j.eururo.2024.03.027_b0270","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.eururo.2012.02.020","article-title":"Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?","volume":"62","author":"Lecouvet","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0275","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/pros.22764","article-title":"One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): toward an upfront simplified \u201call-in-one\u201d imaging approach?","volume":"74","author":"Pasoglou","year":"2014","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2024.03.027_b0280","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.03.027_b0285","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1001\/jama.285.21.2750","article-title":"Cancer screening in elderly patients: a framework for individualized decision making","volume":"285","author":"Walter","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2024.03.027_b0290","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/jama.2010.1923","article-title":"Gait speed and survival in older adults","volume":"305","author":"Studenski","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2024.03.027_b0295","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1002\/cncr.25984","article-title":"Assessing the impact of comorbid illnesses on death within 10 years in prostate cancer treatment candidates","volume":"117","author":"Groome","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2024.03.027_b0300","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.eururo.2024.03.027_b0305","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1471-2318-8-24","article-title":"A standard procedure for creating a frailty index","volume":"8","author":"Searle","year":"2008","journal-title":"BMC Geriatr"},{"key":"10.1016\/j.eururo.2024.03.027_b0310","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1046\/j.1532-5415.2003.51465.x","article-title":"The Mini-Cog as a screen for dementia: validation in a population-based sample","volume":"51","author":"Borson","year":"2003","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.eururo.2024.03.027_b0315","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1200\/JCO.2010.31.2330","article-title":"Impact of comorbidity on survival among men with localized prostate cancer","volume":"29","author":"Albertsen","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.03.027_b0320","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/MOU.0000000000000157","article-title":"Observational studies and the natural history of screen-detected prostate cancer","volume":"25","author":"Albertsen","year":"2015","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0325","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/jso.23584","article-title":"Active surveillance for clinically localized prostate cancer-a systematic review","volume":"109","author":"Thomsen","year":"2014","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.eururo.2024.03.027_b0330","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/nrurol.2017.26","article-title":"Expert consensus document: semantics in active surveillance for men with localized prostate cancer\u2014results of a modified Delphi consensus procedure","volume":"14","author":"Bruinsma","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0335","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.eururo.2019.10.007","article-title":"Randomized study of systematic biopsy versus magnetic resonance imaging and targeted and systematic biopsy in men on active surveillance (ASIST): 2-year post biopsy follow-up","volume":"77","author":"Klotz","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0340","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1097\/JU.0000000000000693","article-title":"The Magnetic Resonance Imaging in Active Surveillance (MRIAS) trial: use of baseline multiparametric magnetic resonance imaging and saturation biopsy to reduce the frequency of surveillance prostate biopsies","volume":"203","author":"Amin","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0345","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.03.027_b0350","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.eururo.2019.09.020","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel consensus statements for deferred treatment with curative intent for localised prostate cancer from an international collaborative study (DETECTIVE study)","volume":"76","author":"Lam","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0355","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/JU.0000000000000526","article-title":"Diagnostic accuracy of prostate biopsy for detecting cribriform Gleason pattern 4 carcinoma and intraductal carcinoma in paired radical prostatectomy specimens: implications for active surveillance","volume":"203","author":"Ericson","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0360","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.juro.2015.04.113","article-title":"Baseline perineural invasion is associated with shorter time to progression in men with prostate cancer undergoing active surveillance: results from the REDEEM study","volume":"194","author":"Moreira","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0365","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/bju.15272","article-title":"Multiparametric magnetic resonance imaging facilitates reclassification during active surveillance for prostate cancer","volume":"127","author":"Fujihara","year":"2021","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.03.027_b0370","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/s41391-021-00373-w","article-title":"Mapping PSA density to outcome of MRI-based active surveillance for prostate cancer through joint longitudinal-survival models","volume":"24","author":"Stavrinides","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2024.03.027_b0375","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00345-018-2420-6","article-title":"Low-risk prostate cancer selected for active surveillance with negative MRI at entry: can repeat biopsies at 1 year be avoided?","volume":"37","author":"Olivier","year":"2019","journal-title":"A pilot study. World J Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0380","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/JU.0000000000001339","article-title":"The clinical significance of multiple negative surveillance prostate biopsies for men on active surveillance\u2014does cancer vanish or simply hide?","volume":"205","author":"Chu","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0385","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.euo.2020.09.004","article-title":"Changes in magnetic resonance imaging using the prostate cancer radiologic estimation of change in sequential evaluation criteria to detect prostate cancer progression for men on active surveillance","volume":"4","author":"O'Connor","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.03.027_b0390","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.euo.2023.01.003","article-title":"Best current practice and research priorities in active surveillance for prostate cancer\u2014a report of a Movember International Consensus Meeting","volume":"6","author":"Moore","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.03.027_b0395","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1056\/NEJMoa1311593","article-title":"Radical prostatectomy or watchful waiting in early prostate cancer","volume":"370","author":"Bill-Axelson","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.03.027_b0400","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa1615869","article-title":"Follow-up of prostatectomy versus observation for early prostate cancer","volume":"377","author":"Wilt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.03.027_b0405","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1136\/jclinpath-2014-202767","article-title":"Prostate biopsy concordance in a large population-based sample: a Surveillance, Epidemiology and End Results study","volume":"68","author":"Schreiber","year":"2015","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.eururo.2024.03.027_b0410","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.eururo.2007.10.008","article-title":"Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy","volume":"53","author":"Yossepowitch","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0415","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2014.01.020","article-title":"Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study","volume":"67","author":"Joniau","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0420","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.eururo.2016.06.023","article-title":"Preoperative membranous urethral length measurement and continence recovery following radical prostatectomy: a systematic review and meta-analysis","volume":"71","author":"Mungovan","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0425","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.euf.2022.01.015","article-title":"Value of different magnetic resonance imaging-based measurements of anatomical structures on preoperative prostate imaging in predicting urinary continence after radical prostatectomy in men with prostate cancer: a systematic review and meta-analysis","volume":"8","author":"van Dijk-de Haan","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2024.03.027_b0430","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1007\/s00330-022-09320-2","article-title":"A standardized method to measure the membranous urethral length (MUL) on MRI of the prostate with high inter- and intra-observer agreement","volume":"33","author":"Veerman","year":"2023","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eururo.2024.03.027_b0435","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.eururo.2016.01.026","article-title":"A critical analysis of the current knowledge of surgical anatomy of the prostate related to optimisation of cancer control and preservation of continence and erection in candidates for radical prostatectomy: an update","volume":"70","author":"Walz","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0440","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/bco2.115","article-title":"Selection of patients for nerve sparing surgery in robot-assisted radical prostatectomy","volume":"3","author":"Vis","year":"2022","journal-title":"BJUI Compass"},{"key":"10.1016\/j.eururo.2024.03.027_b0445","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.eururo.2015.07.029","article-title":"Accuracy of magnetic resonance imaging for local staging of prostate cancer: a diagnostic meta-analysis","volume":"70","author":"de Rooij","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0450","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16410","article-title":"Systematic review and economic modelling of the relative clinical benefit and cost-effectiveness of laparoscopic surgery and robotic surgery for removal of the prostate in men with localised prostate cancer","volume":"16","author":"Ramsay","year":"2012","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.eururo.2024.03.027_b0455","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S1470-2045(18)30357-7","article-title":"Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study","volume":"19","author":"Coughlin","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.03.027_b0460","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.eururo.2016.12.003","article-title":"The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review","volume":"72","author":"Fossati","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0465","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.eururo.2020.11.040","article-title":"Extended versus limited pelvic lymph node dissection during radical prostatectomy for intermediate- and high-risk prostate cancer: early oncological outcomes from a randomized phase 3 trial","volume":"79","author":"Lestingi","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0470","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.euo.2021.03.006","article-title":"Limited versus extended pelvic lymph node dissection for prostate cancer: a randomized clinical trial","volume":"4","author":"Touijer","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.03.027_b0475","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(06)70700-8","article-title":"Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy","volume":"7","author":"Messing","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.03.027_b0480","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2018.04.017","article-title":"Impact of adjuvant radiotherapy in node-positive prostate cancer patients: the importance of patient selection","volume":"74","author":"Abdollah","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0485","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bju.14241","article-title":"Adjuvant radiation with androgen-deprivation therapy for men with lymph node metastases after radical prostatectomy: identifying men who benefit","volume":"123","author":"Gupta","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.03.027_b0490","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","article-title":"Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data","volume":"396","author":"Vale","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2024.03.027_b0495","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1200\/JCO.20.03714","article-title":"Adjuvant versus early salvage radiation therapy for men at high risk for recurrence following radical prostatectomy for prostate cancer and the risk of death","volume":"39","author":"Tilki","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.03.027_b0500","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/j.juro.2013.04.073","article-title":"Predictive factors of oncologic outcomes in patients who do not achieve undetectable prostate specific antigen after radical prostatectomy","volume":"190","author":"Ploussard","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0505","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ijrobp.2014.09.039","article-title":"Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96\u201302 trial","volume":"91","author":"Wiegel","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2024.03.027_b0510","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.eururo.2017.11.024","article-title":"Performance of a prostate cancer genomic classifier in predicting metastasis in men with prostate-specific antigen persistence postprostatectomy","volume":"74","author":"Spratt","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0515","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2019.01.048","article-title":"Persistent prostate-specific antigen after radical prostatectomy and its impact on oncologic outcomes","volume":"76","author":"Preisser","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0520","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13014-018-0983-4","article-title":"Outcome after PSMA PET\/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy","volume":"13","author":"Schmidt-Hegemann","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.eururo.2024.03.027_b0525","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ijrobp.2008.11.007","article-title":"Prospective study evaluating postoperative radiotherapy plus 2-year androgen suppression for post-radical prostatectomy patients with pathologic T3 disease and\/or positive surgical margins","volume":"75","author":"Choo","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2024.03.027_b0530","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s00345-013-1214-0","article-title":"Clinical outcomes after salvage radiotherapy without androgen deprivation therapy in patients with persistently detectable PSA after radical prostatectomy: results from a national multicentre study","volume":"32","author":"Ploussard","year":"2014","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0535","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ijrobp.2007.11.044","article-title":"Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer","volume":"70","author":"Zelefsky","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2024.03.027_b0540","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1007\/s12094-017-1655-9","article-title":"Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer","volume":"19","author":"Zapatero","year":"2017","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.eururo.2024.03.027_b0545","article-title":"Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis","volume":"352","author":"Wallis","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2024.03.027_b0550","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.radonc.2013.09.026","article-title":"Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival","volume":"110","author":"Heemsbergen","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.eururo.2024.03.027_b0555","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0039","article-title":"Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: the NRG Oncology RTOG 0126 randomized clinical trial","volume":"4","author":"Michalski","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2024.03.027_b0560","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ijrobp.2019.02.045","article-title":"Dose escalation for prostate adenocarcinoma: a long-term update on the outcomes of a phase 3, single institution randomized clinical trial","volume":"104","author":"Pasalic","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2024.03.027_b0565","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1001\/jamaoncol.2015.2316","article-title":"Dose-escalated irradiation and overall survival in men with nonmetastatic prostate cancer","volume":"1","author":"Kalbasi","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2024.03.027_b0570","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1470-2045(21)00705-1","article-title":"Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis","volume":"23","author":"Kishan","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.03.027_b0575","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1200\/JCO.22.02390","article-title":"Dose-escalated radiotherapy alone or in combination with short-term androgen deprivation for intermediate-risk prostate cancer: results of a phase III multi-institutional trial","volume":"41","author":"Krauss","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.03.027_b0580","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.03.027_b0585","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6 suppl","key":"10.1016\/j.eururo.2024.03.027_b0590","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.2023.41.6_suppl.304","article-title":"10-Year efficacy and co-morbidity outcomes of a phase III randomised trial of conventional vs. hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CHHiP; CRUK\/06\/016)","volume":"41","author":"Syndikus","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.03.027_b0595","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.03.027_b0600","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.ijrobp.2023.08.027","article-title":"5-Year outcomes from PACE B: an international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) vs. conventionally fractionated or moderately hypo fractionated external beam radiotherapy for localized prostate cancer","volume":"117","author":"van As","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2024.03.027_b0605","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.eururo.2020.01.033","article-title":"Benefits and risks of primary treatments for high-risk localized and locally advanced prostate cancer: an international multidisciplinary systematic review","volume":"77","author":"Moris","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0610","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2024.03.027_b0615","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.brachy.2005.12.002","article-title":"Relationship of the International Prostate Symptom score with urinary flow studies, and catheterization rates following 125I prostate brachytherapy","volume":"5","author":"Martens","year":"2006","journal-title":"Brachytherapy"},{"issue":"Suppl 1","key":"10.1016\/j.eururo.2024.03.027_b0620","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1464-410X.2011.10827.x","article-title":"Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group","volume":"109","author":"Grimm","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.03.027_b0625","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/jcb.2020.92913","article-title":"A history of transurethral resection of the prostate should not be a contra-indication for low-dose-rate (125)I prostate brachytherapy: results of a prospective Uro-GEC phase-II trial","volume":"12","author":"Salembier","year":"2020","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.eururo.2024.03.027_b0630","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.eururo.2011.09.027","article-title":"Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature","volume":"61","author":"Budaus","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0635","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ijrobp.2022.11.005","article-title":"An updated analysis of the survival endpoints of ASCENDE-RT","volume":"115","author":"Oh","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2024.03.027_b0640","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijrobp.2017.01.008","article-title":"ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer","volume":"98","author":"Rodda","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2024.03.027_b0645","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1080\/02841860600710913","article-title":"3-D conformal treatment of prostate cancer to 74 Gy vs. High-dose-rate brachytherapy boost: a cross-sectional quality-of-life survey","volume":"45","author":"Vordermark","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1016\/j.eururo.2024.03.027_b0650","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.ijrobp.2020.11.023","article-title":"Impact of high-dose-rate and low-dose-rate brachytherapy boost on toxicity, functional and cancer outcomes in patients receiving external beam radiation therapy for prostate cancer: a national population-based study","volume":"109","author":"Parry","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2024.03.027_b0655","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19490","article-title":"Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation","volume":"19","author":"Ramsay","year":"2015","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.eururo.2024.03.027_b0660","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.euf.2020.12.016","article-title":"Oncological long-term outcome after whole-gland high-intensity focused ultrasound for prostate cancer-21-yr follow-up","volume":"8","author":"Brundl","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2024.03.027_b0665","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.eururo.2016.02.054","article-title":"Medium-term outcomes after whole-gland high-intensity focused ultrasound for the treatment of nonmetastatic prostate cancer from a multicentre registry cohort","volume":"70","author":"Dickinson","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0670","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/bju.15004","article-title":"Evaluation of functional outcomes after a second focal high-intensity focused ultrasonography (HIFU) procedure in men with primary localized, non-metastatic prostate cancer: results from the HIFU Evaluation and Assessment of Treatment (HEAT) registry","volume":"125","author":"Lovegrove","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.03.027_b0675","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.eururo.2018.06.006","article-title":"A multicentre study of 5-year outcomes following focal therapy in treating clinically significant nonmetastatic prostate cancer","volume":"74","author":"Guillaumier","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0680","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1464-410X.2010.09594.x","article-title":"Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy","volume":"107","author":"Walz","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.03.027_b0685","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eururo.2010.03.001","article-title":"Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng\/ml: a European multi-institutional study of 712 patients","volume":"58","author":"Spahn","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.03.027_b0690","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1464-410X.2005.05394.x","article-title":"Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome","volume":"95","author":"Ward","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.03.027_b0695","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","article-title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study","volume":"11","author":"Bolla","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.03.027_b0700","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.euo.2019.02.001","article-title":"A systematic review of the role of definitive local treatment in patients with clinically lymph node-positive prostate cancer","volume":"2","author":"Ventimiglia","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.03.027_b0705","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824022541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824022541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T13:22:42Z","timestamp":1722518562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283824022541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":141,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0302283824022541"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer\u20142024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}